Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research

Posted by Brenda Bartman on Oct 19th, 2026

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They presently have a $121.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 42.82% from the company’s current price.

A number of other analysts also recently weighed in on SYRE. Wedbush reissued an “outperform” rating and set a $123.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Spyre Therapeutics in a research report on Tuesday, September 1st. UBS Group began coverage on shares of Spyre Therapeutics in a research report on Sunday, October 11th. They set a “buy” rating and a $120.00 price target for the company. Guggenheim raised their price target on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. began coverage on shares of Spyre Therapeutics in a research report on Thursday, October 1st. They set an “overweight” rating and a $110.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.40.

Check Out Our Latest Stock Analysis on Spyre Therapeutics

Spyre Therapeutics Stock Up 6.0%

Shares of SYRE traded up $4.82 during mid-day trading on Monday, reaching $84.72. 1,272,037 shares of the stock traded hands, compared to its average volume of 1,140,896. Spyre Therapeutics has a 12-month low of $21.15 and a 12-month high of $110.18. The firm has a market cap of $8.63 billion, a price-to-earnings ratio of -43.45 and a beta of 3.10. The stock has a fifty day simple moving average of $91.99 and a 200 day simple moving average of $84.39.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.40. On average, equities research analysts expect that Spyre Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $92.01, for a total value of $1,380,150.00. Following the completion of the transaction, the chief executive officer owned 537,540 shares of the company’s stock, valued at $49,459,055.40. The trade was a 2.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Albers sold 18,000 shares of Spyre Therapeutics stock in a transaction on Friday, August 7th. The stock was sold at an average price of $104.55, for a total transaction of $1,881,900.00. Following the completion of the transaction, the director directly owned 9,360 shares of the company’s stock, valued at approximately $978,588. This represents a 65.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 183,564 shares of company stock worth $16,903,193. Company insiders own 15.69% of the company’s stock.

Hedge Funds Weigh In On Spyre Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC acquired a new position in Spyre Therapeutics in the second quarter worth $31,000. Summit Securities Group LLC acquired a new position in Spyre Therapeutics in the first quarter worth $28,000. GAMMA Investing LLC boosted its holdings in Spyre Therapeutics by 26.8% in the second quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after purchasing an additional 140 shares during the period. IFP Advisors Inc boosted its holdings in Spyre Therapeutics by 3,241.7% in the third quarter. IFP Advisors Inc now owns 802 shares of the company’s stock worth $71,000 after purchasing an additional 778 shares during the period. Finally, KBC Group NV acquired a new position in Spyre Therapeutics in the first quarter worth $69,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics.

Spyre’s investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A.